This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Issa, J.-P. J. Search for Related Content PubMed PubMed Citation Articles by Issa, J.-P. J.

DNA Methylation as a Therapeutic Target in Cancer

Author's Affiliation: University of Texas M.D. Anderson Cancer Center, Houston, Texas

Requests for reprints: Jean-Pierre J. Issa, Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Unit 428, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-745-2260; Fax: 713-794-4297; E-mail: jpissa{at}mdanderson.org.

Abstract

Targeting DNA methylation for cancer therapy has had a rocky history. The first reports on DNA methylation changes in cancer described global loss of methylation, which has been suggested to drive tumorigenesis through activation of oncogenic proteins or induction of chromosomal instability. In this context, reducing DNA methylation was viewed as a tumor-promoting event rather than a promising cancer therapy. The idea of inhibiting DNA methylation therapeutically emerged from subsequent studies showing that, in parallel to global decreases in methylation, several genes (including many critical to the tumor phenotype) displayed gains of methylation in their promoters during tumorigenesis, a process associated with epigenetic silencing of expression and loss of protein function. This led to revival of interest in drugs discovered decades ago to be potent inhibitors of DNA methyltransferases. These drugs have now been approved for clinical use in the United States in the treatment of myelodysplastic syndrome, thus opening the floodgate for a whole new approach to cancer therapy—epigenetic therapy.

This article has been cited by other articles:

				S. D. Nimer Myelodysplastic syndromes Blood, May 15, 2008; 111(10): 4841 - 4851. [Abstract] [Full Text] [PDF]

				E.-S. Lee, J.-P. Issa, D. B. Roberts, M. D. Williams, R. S. Weber, M. S. Kies, and A. K. El-Naggar Quantitative Promoter Hypermethylation Analysis of Cancer-Related Genes in Salivary Gland Carcinomas: Comparison with Methylation-Specific PCR Technique and Clinical Significance Clin. Cancer Res., May 1, 2008; 14(9): 2664 - 2672. [Abstract] [Full Text] [PDF]

				A. M. Devlin, R. Singh, R. E. Wade, S. M. Innis, T. Bottiglieri, and S. R. Lentz Hypermethylation of Fads2 and Altered Hepatic Fatty Acid and Phospholipid Metabolism in Mice with Hyperhomocysteinemia J. Biol. Chem., December 21, 2007; 282(51): 37082 - 37090. [Abstract] [Full Text] [PDF]

				E. R. Plimack, D. J. Stewart, and J.-P. J. Issa Combining Epigenetic and Cytotoxic Therapy in the Treatment of Solid Tumors J. Clin. Oncol., October 10, 2007; 25(29): 4519 - 4521. [Full Text] [PDF]

				T. Qin, E. M. Youssef, J. Jelinek, R. Chen, A. S. Yang, G. Garcia-Manero, and J.-P. J. Issa Effect of Cytarabine and Decitabine in Combination in Human Leukemic Cell Lines Clin. Cancer Res., July 15, 2007; 13(14): 4225 - 4232. [Abstract] [Full Text] [PDF]